Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.
Quote | Medigene Ag Ord (OTCMKTS:MDGEF)
Last: | $2.43 |
---|---|
Change Percent: | 0.0% |
Open: | $2.43 |
Close: | $2.43 |
High: | $2.43 |
Low: | $2.43 |
Volume: | 500 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Medigene Ag Ord (OTCMKTS:MDGEF)
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Message Board Posts | Medigene Ag Ord (OTCMKTS:MDGEF)
Subject | By | Source | When |
---|---|---|---|
dhovekamp42: Attention will come with this 1st commercial TCR immunotherapy deal of German Medigene | dhovekamp42 | investorshangout | 09/29/2016 8:02:37 AM |
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...